JUPITER NEUROSCIENCES, INC. Increase (Decrease) in Accounts Payable and Accrued Liabilities
JUPITER NEUROSCIENCES, INC. (JUNS) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $279.60 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-14
- JUPITER NEUROSCIENCES, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $443.61K, a 52.42% increase year-over-year.
- JUPITER NEUROSCIENCES, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was -$164.01K.
- JUPITER NEUROSCIENCES, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was $160.29K.
- JUPITER NEUROSCIENCES, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was -$95.61K, a 215.15% decline year-over-year.
- JUPITER NEUROSCIENCES, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was $242.16K.
- JUPITER NEUROSCIENCES, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was -$149.53K, a 190.69% decline from fiscal 2023.
- JUPITER NEUROSCIENCES, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was $164.88K.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $443.61K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $279.60K 10-Q · filed 2026-08-14 | $439.89K derived: sum of 3 quarters · filed 2026-08-14 | $344.28K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$164.01K 10-Q · filed 2026-05-14 | -$3.72K derived: sum of 2 quarters · filed 2026-05-14 | -$99.33K derived: sum of 3 quarters · filed 2026-05-14 | $191.71K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $160.29K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-01 | $64.68K derived: sum of 2 quarters · filed 2026-04-01 | $355.71K derived: sum of 3 quarters · filed 2026-08-14 | $242.16K 10-K · filed 2026-04-01 |
| 2025-09-30 | -$95.61K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $195.42K derived: sum of 2 quarters · filed 2026-08-14 | $81.87K 10-Q · filed 2025-11-14 | -$185.22K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $291.03K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $177.48K 10-Q · filed 2026-08-14 | -$89.60K derived: sum of 3 quarters · filed 2026-08-14 | -$6.57K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$113.55K 10-Q · filed 2026-05-14 | -$380.64K derived: sum of 2 quarters · filed 2026-05-14 | -$297.61K derived: sum of 3 quarters · filed 2026-05-14 | -$276.29K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$267.08K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-01 | -$184.05K derived: sum of 2 quarters · filed 2026-04-01 | -$162.74K derived: sum of 3 quarters · filed 2026-04-01 | -$149.53K 10-K · filed 2026-04-01 |
| 2024-09-30 | $83.03K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $104.35K derived: sum of 2 quarters · filed 2025-11-14 | $117.56K 10-Q · filed 2025-11-14 | $78.50K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $21.32K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-19 | $34.52K 10-Q · filed 2025-08-19 | -$4.53K derived: sum of 3 quarters · filed 2025-08-19 | |
| 2024-03-31 | $13.21K 10-Q · filed 2025-05-15 | -$25.85K derived: sum of 2 quarters · filed 2025-05-15 | ||
| 2023-12-31 | -$39.06K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $164.88K 10-K · filed 2025-03-28 | ||
| 2023-09-30 | $203.94K 10-Q · filed 2024-12-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |